RASGEF1A — RasGEF Domain Family Member 1A
Introduction
Rasgef1A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@rasmapk2019]
<table> [@erk2020]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">RASGEF1A</th></tr> [@ras2021]
<tr><td><strong>Gene Symbol</strong></td><td>RASGEF1A</td></tr> [@therapeutic2022]
<tr><td><strong>Full Name</strong></td><td>RasGEF Domain Family Member 1A</td></tr>
<tr><td><strong>Chromosome</strong></td><td>10q21.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[54974](https://www.ncbi.nlm.nih.gov/gene/54974)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607619](https://www.omim.org/entry/607619)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000165682</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q8IUR5](https://www.uniprot.org/uniprot/Q8IUR5)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Cancer, Neurodegeneration, Developmental Disorders</td></tr>
</table>
</div>
Overview
RasGEF Domain Family Member 1A (RASGEF1A) is a member of the Ras guanine nucleotide exchange factor (RasGEF) family that catalyzes the exchange of GDP for GTP on Ras proteins, thereby activating Ras signaling pathways. Ras proteins are small GTPases that function as molecular switches controlling cell proliferation, differentiation, survival, and synaptic plasticity. Dysregulated Ras signaling contributes to cancer development and has been implicated in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). RASGEF1A is expressed in various tissues, with particular abundance in brain, and plays important roles in neuronal function and development.
Function
Ras Activation via GEF Activity
RasGEF1A contains a conserved RasGEF domain that catalyzes the activation of Ras proteins by promoting the exchange of bound GDP for GTP. This activity is essential for:
- Initiating Ras-MAPK signaling cascades
- Transducing extracellular signals to intracellular responses
- Coordinating cell growth, differentiation, and survival
The Ras family includes H-Ras, N-Ras, K-Ras4A, and K-Ras4B, all of which can be activated by RasGEF family members. Different GEFs show selectivity for specific Ras isoforms, influencing downstream pathway activation.
Ras-MAPK Signaling Pathway
Activated Ras proteins recruit and activate RAF kinases (ARAF, BRAF, RAF1), which initiate the MAPK/ERK cascade:
- RAF phosphorylates and activates MEK1/2
- MEK1/2 phosphorylates and activates ERK1/2
- ERK translocates to the nucleus and activates transcription factors
This pathway regulates:
- Cell cycle progression (cyclin D1 expression)
- Gene expression (c-Fos, c-Myc, Egr1)
- Neuronal plasticity (synaptic strengthening, memory formation)
- Cell survival (Bcl-2 family regulation)
Neuronal Functions
In [neurons](/entities/neurons), Ras-MAPK signaling is critical for:
- [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and memory formation
- Synaptic plasticity and dendritic spine morphology
- Axonal growth and guidance during development
- Neuronal survival and stress responses
- Regulation of ion channel function
Cell Cycle Regulation
Ras-MAPK signaling drives cell cycle progression from G0/G1 to S phase. Dysregulated signaling can lead to:
- Uncontrolled proliferation (cancer)
- Abnormal neuronal differentiation
- Cell cycle re-entry in neurons (a pathological event in neurodegeneration)
Disease Associations
Cancer
RasGEF1A dysregulation contributes to oncogenesis through:
- Overexpression in various tumor types
- Enhanced Ras-MAPK signaling
- Increased cell proliferation and survival
Multiple cancers show elevated RASGEF1A expression, including:
- Lung carcinoma
- Colorectal cancer
- Breast cancer
- Glioma
Neurodegenerative Diseases
Alzheimer's Disease:
- Ras-MAPK signaling is hyperactivated in AD brain
- ERK1/2 activation is associated with [tau](/proteins/tau) pathology
- MAPK signaling contributes to [amyloid-beta](/proteins/amyloid-beta) toxicity
- RasGEF1A expression may be altered in AD
Parkinson's Disease:
- Ras-MAPK signaling is involved in dopaminergic neuron survival
- Neurotrophic factor signaling uses Ras pathways
- Oxidative stress activates MAPK cascades
- RasGEF1A may modify PD risk
Huntington's Disease:
- Mutant [huntingtin](/proteins/huntingtin) disrupts Ras-MAPK signaling
- Transcriptional dysregulation involves MAPK pathways
- Ras signaling modulates neuronal vulnerability
- Potential therapeutic targets in this pathway
Amyotrophic Lateral Sclerosis (ALS):
- MAPK activation in motor neurons
- Inflammation-related signaling
- Stress response pathways
Developmental Disorders
Rasopathies are developmental syndromes caused by Ras-MAPK pathway dysregulation:
- Noonan syndrome
- Cardiofaciocutaneous syndrome
- Costello syndrome
While RASGEF1A is not typically mutated in these conditions, it participates in the same pathway.
Expression
RASGEF1A is expressed in various tissues:
- Brain (highest expression)
- Lung
- Kidney
- Heart
- Testis
- Lymphoid tissues
In the brain, RASGEF1A is expressed in:
- Cerebral [cortex](/brain-regions/cortex) (layers II-IV)
- [Hippocampus](/brain-regions/hippocampus) (CA1-CA3, dentate gyrus)
- Cerebellum (Purkinje cells, granule cells)
- Basal ganglia
- Substantia nigra
Expression is developmentally regulated, with highest levels during brain development.
Therapeutic Implications
Cancer Therapy
Targeting Ras-MAPK pathway:
- MEK inhibitors (trametinib, cobimetinib)
- RAF inhibitors (vemurafenib, dabrafenib)
- Combination strategies
Neurodegeneration
Modulating Ras-MAPK signaling:
- MAPK pathway inhibitors for neuroprotection
- Enhancement of neurotrophic factor signaling
- Targeting specific downstream effectors
Cross-links
- [MAPK Signaling Pathway](/mechanisms/mapk-signaling-neurodegeneration)
- [Ras Proteins](/entities/ras-proteins)
- [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
- [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
- [ERK Signaling](/mechanisms/erk-signaling)
See Also
- [Genes Index](/genes)
- [Signal Transduction](/entities/signal-transduction)
- [RASGRF1](/genes/rasgrf1)
- [RASGRP1](/genes/rasgrp1)
Background
The study of Rasgef1A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[Unknown, RasGEF family: structure and function (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29890892/)
[Unknown, Ras-MAPK signaling in neurodegeneration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31147256/)
[Unknown, ERK activation in Alzheimer's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32215923/)
[Unknown, Ras GTPases in neuronal function (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34012547/)
[Unknown, Therapeutic targeting of Ras pathways in cancer (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35038421/)